Rosuvastatin Decreases Mean Platelet Volume in Patients With Diabetes Mellitus

Abstract

Statins have multiple effects (also known as pleiotropic effects) on inflammation, plaque stabilization, endothelial function, and hemostasis. We evaluated the effects of rosuvastatin on mean platelet volume (MPV)--a marker for platelet activity--in patients with diabetes mellitus (DM) on rosuvastatin medication. Patients (n = 178) who were to be prescribed high-intensity rosuvastatin were retrospectively enrolled according to their medical records. Baseline and 6-month biochemical tests, automated blood count, cell-volume analysis, and their cardiovascular risk factors were recorded. Rosuvastatin significantly reduced the MPV and the lipid parameters including total cholesterol, triglyceride, and low-density lipoprotein cholesterol (LDL-C). However, there was no correlation between MPV and LDL-C before (r = -.66; P = .383) and after (r = -.112; P = .135) rosuvastatin treatment or between ΔMPV and ΔLDL-C after 40 mg rosuvastatin daily therapy (r = -.155; P = .073). Rosuvastatin significantly decreases the MPV as well as cholesterol levels. The antiplatelet activation properties of high-dose rosuvastatin treatment in patients with DM are not lipid dependent.

Association between mean platelet volume and hypertension incidence

“…16,17 Hypoglycemic or hypolipidemic decreases the MPV as well as plasma glucose level 18 or cholesterol levels. 19 Hundreds of participants of this study are taking hypoglycemic agent or hypolipidemic agent, may decrease the association between MPV and hypertension incidence, because individuals with diabetes or dyslipidemia have higher hypertension incidence even on treat. Changes in MPV are chronic rather than abrupt, which is another indication that it correlates with chronic diseases such as hypertension.…”

Retraction Notice

“…22 Yet other studies showed an effect of statins on the MPV. [23][24][25] The MPV levels, total numbers of white blood cells, platelets, and lymphocytes were determined by the Coulter LH Series (Beckman Coulter, Inc., Hialeah, Florida). Because MPV expands with time in EDTA, complete blood count studies were done as soon as possible (within 30 minutes) after the blood samples were drawn to minimize changes in platelet size.…”

Rosuvastatin and Mean Platelet Volume in Diabetes

“…With rosuvastatin this action is not mediated by the improved serum lipids, 28 whereas atorvastatin achieved a significant MPV reduction in patients with the strongest concomitant lipid changes. 25 This emerging difference needs to be revisited.…”

“…25 Conversely, pravastatin treatment did not lower the MPV. 27 More recently, the study of Akyüz et al 28 examined 178 patients with DM receiving high-dose rosuvastatin (40 mg/d) for dyslipidemia. After 6 months of treatment, there was a significant (P < .001) decrease in MPV.…”